Holocene Advisors’s Cymabay Therapeutics CBAY Stock Holding History

Holocene Advisors’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,993,945	Closed	-$70.7M	–	905
2023 Q4	$70.7M	Sell	2,993,945 -123,740	-4%	-$2.2M	0.28%	118
2023 Q3	$46.5M	Buy	+3,117,685	New	+$41.3M	0.2%	144

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Holocene Advisors's CBAY Position: Q1 2024 in Review

Holocene Advisors sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 2,993,945 shares — an estimated $70.7M sold.

Holocene Advisors first reported a position in CBAY in Q3 2023 and held it in 2 quarters. The position peaked at $70.7M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

Holocene Advisors reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
Holocene Advisors sold 2,993,945 Cymabay Therapeutics shares in Q1 2024, an estimated $70.7M.
Holocene Advisors first reported a position in Cymabay Therapeutics in Q3 2023 and held it in 2 quarters.
Holocene Advisors's Cymabay Therapeutics position peaked at $70.7M in Q4 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Holocene Advisors's 13F filing for Q1 2024, filed 15 May 2024.